Protein-Protein Interaction Details
Protein General Information (TTD Target) | Top | ||||
---|---|---|---|---|---|
Full Name | IL-1 receptor-associated kinase 1 (IRAK1) | Patented-recorded | Target Info | ||
UniProt ID | IRAK1_HUMAN | ||||
Gene Name | IRAK1 | ||||
Gene ID | 3654 |
Interacting TTD Target Information | Top | ||||
---|---|---|---|---|---|
Interacting Successful Target(s) | Interleukin 1 receptor type 1 (IL1R1) | Target Info | PPI Info | [1] | |
Interacting Clinical trial Target(s) | Renal carcinoma antigen NY-REN-64 (IRAK-4) | Target Info | PPI Info | [2] | |
Interacting Patented-recorded Target(s) | IL-1 receptor-associated kinase 1 (IRAK1) | Target Info | PPI Info | [3] | |
Interacting Literature-reported Target(s) | Myeloid differentiation primary response protein MyD88 (MYD88) | Target Info | PPI Info | [4] | |
IL-1 receptor-associated kinase 3 (IRAK3) | Target Info | PPI Info | [3] | ||
TNF receptor-associated factor 6 (TRAF6) | Target Info | PPI Info | [5] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR . J Biol Chem. 2003 May 9;278(19):16713-9. | ||||
REF 2 | Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med. 2003 Jan 20;197(2):263-8. | ||||
REF 3 | Regulation of IRAK-1 activation by its C-terminal domain. Cell Signal. 2009 May;21(5):719-26. | ||||
REF 4 | A20-binding inhibitor of NF-B (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein activation and protects from inflammatory disease. Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):E998-1006. | ||||
REF 5 | TRAF6 is a signal transducer for interleukin-1. Nature. 1996 Oct 3;383(6599):443-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.